Thrombin-induced reactive oxygen species generation in platelets: A novel role for protease-activated receptor 4 and GPIbα  by Carrim, Naadiya et al.
Redox Biology 6 (2015) 640–647Contents lists available at ScienceDirectRedox Biologyhttp://d
2213-23
Abbre
collagen
n Corr
WA 610
E-mjournal homepage: www.elsevier.com/locate/redoxResearch PaperThrombin-induced reactive oxygen species generation in platelets:
A novel role for protease-activated receptor 4 and GPIbα
Naadiya Carrim a, Jane F. Arthur c, Justin R. Hamilton c, Elizabeth E. Gardiner c,
Robert K. Andrews c, Niamh Moran b, Michael C. Berndt a,d, Pat Metharoma,d,e,n
a Department of Experimental Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland
b Department of Molecular Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland
c Australian Centre for Blood Diseases, Monash University, Melbourne, Australia
d Faculty of Health Sciences, Curtin University, Perth, Australia
e Curtin Health Innovation Research Institute, Curtin University, Perth, Australiaa r t i c l e i n f o
Article history:
Received 13 October 2015
Received in revised form
23 October 2015
Accepted 23 October 2015
Available online 28 October 2015
Keywords:
Platelets
Reactive oxygen species
Thrombin
Receptors GPIbα
PAR1 and PAR4x.doi.org/10.1016/j.redox.2015.10.009
17/& 2015 The Authors. Published by Elsevier
viations: ROS, reactive oxygen species; Nk, N
-related peptide; WT, wild type; PAR, protea
espondence to: Faculty of Health Sciences Cur
2, Australia.
ail address: pat.metharom@curtin.edu.au (P. Ma b s t r a c t
Background: Platelets are essential for maintaining haemostasis and play a key role in the pathogenesis
of cardiovascular disease. Upon ligation of platelet receptors through subendothelial matrix proteins,
intracellular reactive oxygen species (ROS) are generated, further amplifying the platelet activation re-
sponse. Thrombin, a potent platelet activator, can signal through GPIbα and protease-activated receptor
(PAR) 1 and PAR4 on human platelets, and recently has been implicated in the generation of ROS. While
ROS are known to have key roles in intra-platelet signalling and subsequent platelet activation, the
precise receptors and signalling pathways involved in thrombin-induced ROS generation have yet to be
fully elucidated.
Objective: To investigate the relative contribution of platelet GPIbα and PARs to thrombin-induced re-
active oxygen species (ROS) generation.
Methods and results: Highly speciﬁc antagonists targeting PAR1 and PAR4, and the GPIbα-cleaving en-
zyme, Naja kaouthia (Nk) protease, were used in quantitative ﬂow cytometry assays of thrombin-induced
ROS production. Antagonists of PAR4 but not PAR1, inhibited thrombin-derived ROS generation. Removal
of the GPIbα ligand binding region attenuated PAR4-induced and completely inhibited thrombin-in-
duced ROS formation. Similarly, PAR4 deﬁciency in mice abolished thrombin-induced ROS generation.
Additionally, GPIbα and PAR4-dependent ROS formation were shown to be mediated through focal ad-
hesion kinase (FAK) and NADPH oxidase 1 (NOX1) proteins.
Conclusions: Both GPIbα and PAR4 are required for thrombin-induced ROS formation, suggesting a novel
functional cooperation between GPIbα and PAR4. Our study identiﬁes a novel role for PAR4 in mediating
thrombin-induced ROS production that was not shared by PAR1. This suggests an independent signalling
pathway in platelet activation that may be targeted therapeutically.
& 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Platelets are essential for maintaining haemostasis and play a
key role in the pathogenesis of cardiovascular disease [1]. Upon
ligation of platelet receptors through subendothelial matrix pro-
teins, intracellular reactive oxygen species (ROS) are generated and
released, further amplifying the platelet activation response [2–4].
The main source of ROS is through NADPH oxidase (NOX)B.V. This is an open access article u
aja kaouthia protease; CRP,
se-activated receptor
tin University Bentley, Perth,
etharom).activation [5], and both NOX1 and NOX2 are expressed in human
platelets [6]. We previously described a role for NOX1 in GPVI-
dependent thrombus formation [7], suggesting platelet-derived
ROS are a potential therapeutic target against cardiovascular dis-
ease. Recently, thrombin has been implicated in the generation of
ROS [2,3]. While ROS are known to have key roles in intra-platelet
signalling [8] and subsequent platelet activation [4], the precise
receptors and signalling pathways involved in thrombin-induced
ROS generation have yet to be fully elucidated.
Thrombin, a potent platelet activator, can signal through GPIbα
and protease activated receptor (PAR)1 and PAR4 on platelets [9].
PAR1 and PAR4 are known as the major thrombin receptors on
platelets [10]; however, thrombin additionally binds GPIbα in-
itiating the phosphorylation of signalling molecules required fornder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
N. Carrim et al. / Redox Biology 6 (2015) 640–647 641integrin αIIbβ3 activation [11,12]. This signalling is inhibited by
treatment of platelets with the puriﬁed snake venom-derived
metalloproteinases, mocarhagin and Naja kaouthia (Nk) protease
[12,13], which cleave GPIbα between amino acids Glu282-Asp283
and Tyr276-Asp277, respectively, to remove the GPIbα ectodomain
including a sulphated tyrosine sequence that binds thrombin
[14,15]. In human platelets both PAR1 and PAR4 initiate platelet
activation through G-protein signalling, and PAR1 contains a
thrombin-binding sequence, which is absent in PAR4, allowing
thrombin to bind more readily (20–70-fold faster rate of activation
than PAR4) and at lower concentrations [16,17]. Human platelets
possess both PAR1 and PAR4 receptors in similar numbers (ap-
proximately 1000 copies/platelet) [18,19], however mouse plate-
lets do not express PAR1 and activation occurs through PAR4 [20].
Distinct differences have been reported between PAR1 and
PAR4 signalling in human platelets [21]. Calcium responses elicited
through PAR1 are short and rapid, but prolonged and sustained
following PAR4 stimulation [17]. PAR4, but not PAR1, is regulated
by P2Y12-stimulated feedback [22], and desensitisation of PAR1 in
platelets is overcome by signalling through PAR4 [23]. Further-
more, stimulation of PAR4 results in more robust procoagulant
activity in comparison to PAR1 [24].
Both thrombin and the PAR1-speciﬁc agonist thrombin re-
ceptor-activating peptide as well as GPVI and FcγRIIa agonists
stimulate ROS production in platelets [2,7,25]; however GPIbα-
and PAR4-speciﬁc agonists have not been evaluated as to whether
they induce ROS formation. To investigate the relative contribu-
tions of thrombin receptors to ROS generation, platelets were
treated with highly speciﬁc PAR1 and PAR4 antagonists or, Nk
protease, and subsequently ROS production was quantiﬁed by ﬂow
cytometry. Here, we provide evidence for functional roles for
GPIbα and PAR4 in thrombin-induced ROS generation, in-
dependent of PAR1, and a potential synergy between GPIbα and
PAR4. Furthermore, ROS produced via GPIbα and PAR4 activation
are mediated through focal adhesion kinase (FAK) and NOX1.2. Materials and methods
2.1. Materials
Anti-GPIbα (AK2) and anti-VWF (5D2) murine monoclonal
antibodies have been previously described [26,27]; the irrelevant
isotype IgG2 was from BD Pharmingen (Oxford, UK). Rat anti-
mouse GPIbα (Xia.G5) IgG2B and rat IgG2B isotype (both FITC
conjugated) were obtained from Emfret (Würzburg, Germany).
Cross-linked collagen related peptide (CRP) was obtained from
Prof. Richard Farndale (Department of Biochemistry, Cambridge
University, UK). The protein kinase C activator, phorbol myristoyl
acetate (PMA), and the calcium ionophore, A23187, were from
Sigma Aldrich (St. Louis, MO, USA). Thrombin was from Calbio-
chem (UK). PAR1 (PAR1-AP, SFLLRN-NH2) and PAR4 (PAR4-AP,
AYPGKF-NH2) agonists were from Abgent Europe (Oxfordshire,
UK). PAR4 antagonist, tcY-NH2, PAR1 antagonist, SCH79797, and
PF-573228 (hereafter referred to as PF-228) were from Tocris
Bioscience (R&D Systems Europe, UK). ML171 (2-acet-
ylphenothiazine) and BMS200261 were purchased from Sigma
Aldrich (St. Louis, MO, USA). Nk protease (a GPIbα-speciﬁc clea-
vage enzyme from the venom of cobra Naja kaouthia) was puriﬁed
as previously described [28].
2.2. Preparation of washed human and mouse platelets
Blood collection from drug-free healthy volunteers was ap-
proved by the Medical Research Ethics Committee of the Royal
College of Surgeons in Ireland (RCSI), ID number REC269, and theAustralian Centre for Blood Diseases (ACBD), Monash University,
Melbourne, Australia. Written informed consent was obtained
from all donors prior to phlebotomy. Venous blood was drawn
using acid citrate dextrose (ACD-15% v/v) as anticoagulant. In brief,
platelet-rich plasma (PRP) was obtained by centrifugation of
whole blood at 190g for 20 min without braking. Platelets were
isolated from PRP by centrifugation for 8 min at 650g, resuspended
and washed (3x) in CGS buffer (123 mM NaCl, 33.3 mM glucose,
14.7 mM trisodium citrate, pH 7.0). Platelets were resuspended to
the required count in Ca2þ-free HEPES Tyrode's buffer (5 mM
HEPES, 5.5 mM glucose, 138 mM NaCl, 12 mM NaHCO3, 0.49 mM
MgCl2, 2.6 mM KCl, 0.36 mM NaH2PO4, pH 7.4). Platelets were
supplemented with 1.8 mM CaCl2 prior to experimentation.
Studies using platelets from PAR4 knock out (KO) mice were
performed at the ACBD (Monash University, Melbourne, Australia).
Blood was drawn by approved personnel, with approval from the
corresponding local Ethics Committee. Platelets were prepared as
described previously [7] with one noted exception: mice were
overdosed with pentobarbitone (60 mg/kg) prior to blood collec-
tion. The generation and characterisation of the PAR4 KO mice
have been previously described [29]. Age- and sex-matched wild-
type (WT) littermates were used as controls.
2.3. Platelet aggregation
Platelet aggregation was preformed in a PAP 4-C aggregometer
(Chrono-Log, PA, USA) using washed platelets (2.5108/mL) un-
der constant stirring at 1100 rpm at 37 °C. For all inhibitory studies
throughout this study, platelets were preincubated with vehicle
control or antagonists for 10 min at 37 °C before the addition of
agonist.
2.4. Measurement of intracellular ROS
The measurement of intracellular ROS was performed as pre-
viously described [7,30]. Brieﬂy, washed platelets (2.5108/mL) in
HEPES Tyrode's were incubated for 30 min at 37 °C with 10 mM
dihydrodichloroﬂuorescein diacetate (H2DCFDA, Cambridge
Bioscience, UK), pre-treated with antagonists then stimulated with
1 mg/mL of CRP for 10 min at 37 °C. Samples were diluted 10-fold
in HEPES Tyrode's (0.1% BSA) containing 10 mM H2DCFDA and
analysed immediately. All ﬂow cytometric analysis was performed
on a FACSCanto™ II (in Ireland) or FACSCalibur™ (in Australia) and
analysed using FACSDiva™ software (Becton Dickinson, San Jose,
CA, USA). ROS stimulation indexes were calculated from the
ﬂuorescent geo-mean values expressed as fold change relative to
unstimulated platelet sample set as 1. In some instances, to show
effects of inhibitors, positive controls were set as 100% ROS pro-
duction. It must be noted that H2DCFDA has some limitations [31].
The dye is preferentially oxidised by a variety of one-electron
species including hydroxyl radicals, peroxyl radicals and perox-
ynitrite anions, and therefore does not offer a direct measurement
of H2O2. Additionally, a degree of self-propagating signal ampliﬁ-
cation is involved once DCF radical is generated. Nevertheless, as
shown in our previous study, ﬂuorescent signal generated by
H2DCFDA-loaded activated platelets could be abrogated by a spe-
ciﬁc NADPH oxidase inhibitor, ML171. This reduction of H2DCFDA-
oxidising species corroborated with an impact on platelet func-
tional response, speciﬁcally thromboxane production and throm-
bus forming ability [7].
2.5. Nk protease treatment of platelets
Washed platelets (1109/mL) were resuspended in HEPES
Tyrode's buffer with Ca2þ and incubated with or without 10 mg/mL
of Nk protease for 30 min at 37 °C. Platelets were washed with CGS
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in HEPES Tyrode's buffer with Ca2þ at 2.5108/mL.
2.6. Measurement of GPIbα cleavage
Washed platelets (2.5108/mL) treated with or without Nk
protease (10 mg/mL) were incubated with the PE-labelled GPIbα-
speciﬁc antibody (2 mg/mL AN51) or isotype control (2 mg/mL) for
15 min at 37 °C, then diluted 100-fold in HEPES Tyrode's and
measured for intact GPIbα content on a FACSCanto™.
2.7. Cell lines
COS-7 cells and COS-7 cells stably expressing the VWF-A1 do-
main containing an R543W mutation (a gain-of-function mutation
found in Type 2B von Willebrand's Disease), hereafter designated
as R543W cells, have been described previously [32]. The cell lines
were grown and maintained in M199 medium supplemented with
2 mM glutamine, 10% (v/v) FBS and 1 mg/mL puromycin at 37 °C
and 5% CO2 prior to use.
2.8. Analysis of COS-7 cells expressing VWF-A1 domain
The level of VWF-A1/R543W on transfected COS-7 cells was
assessed by ﬂow cytometry. Cells were harvested using TBS con-
taining 10 mM EDTA, pelleted, washed and resuspended (2.5107
cells/mL) in HEPES Tyrode's buffer. Cells were pre-incubated with
either 10 mg/mL of mouse monoclonal antibodies anti-VWF (5D2)
or 20 mg/mL anti-GPIbα (AK2, negative control) for 1 h at room
temperature, washed, incubated for a further 30 min with anti-Fig. 1. ROS generation through the activation of PARs. Washed human platelets (preload
2 U/mL thrombin, (B) 10–50 mM PAR1-AP or (C) 150–250 mM PAR4-AP, and monitored
cytometry (n¼3). (D) Platelet-derived ROS generation stimulated with PAR1-AP (50 mM),
mean7SEM (n¼3), ***Pr0.001.mouse FITC secondary antibody, washed, and resuspended in
200 mL HEPES Tyrode's for analysis on a FACSCalibur™.
2.9. Data analysis
All statistical analysis was performed using GraphPad Prism 5
s
.
Results are shown as mean7SEM. Statistical signiﬁcance of dif-
ference between means was determined using ANOVA, with post-
hoc analysis by the Bonferroni test. A value of *Pr0.05 was con-
sidered to be statistically signiﬁcant.3. Results
3.1. Detection of ROS following PAR1 and PAR4 activation
Platelet-derived ROS generation through thrombin receptors
was assessed using PAR1 and PAR4 agonists and thrombin. Fig. 1
shows aggregation and ROS generation of washed human platelets
stimulated with increasing concentrations of thrombin, PAR1-AP
and PAR4-AP. While thrombin at 0.2, 1 and 2 U/mL elicited max-
imal platelet aggregation responses, ROS generation was only
measurable at 1–2 U/mL (Fig. 1A) consistent with other reports [2,
3,33], suggesting a predominant role for PAR4 and not PAR1 in
thrombin-dependent ROS production.
Previous studies have demonstrated ROS production through
PAR1 activation in platelets [3], but a role for PAR4 in platelet
generated ROS has not been previously described. Here, PAR1 ac-
tivation induced maximum platelet aggregation at concentrations
as low as 10 mM but required higher concentrations (20–50 mM) toed with 10 mM H2DCFDA for ROS experiments only) were stimulated with (A) 0.2–
for aggregation by light transmission aggregometry or ROS production by ﬂow
PAR4-AP (250 mM) and thrombin (1 U/mL) from the same platelet samples. Data are
Fig. 2. Thrombin-induced ROS generation requires PAR4, but not PAR1. (A) H2DCFDA labelled human platelets were pre-treated with vehicle control (0.1% DMSO), PAR1
antagonist SCH79797 (1 mM) or PAR4 antagonist tcY-NH2 (400 mM), stimulated with thrombin (2 U/mL), and monitored for ROS production by ﬂow cytometry. Data are
mean7SEM (n¼3), *Pr0.05, ***Pr0.001. (B) Washed platelets from WT and PAR4 KO mice (2.5108/mL) were preloaded with 10 mM H2DCFDA and left unstimulated, or
stimulated with thrombin (2 U/mL) and ROS production was measured by ﬂow cytometry. Data are mean7SEM (n¼3), *Po0.05 H2DCFDA labelled platelets from WT and
PAR4 KO mice were left unstimulated, or stimulated with thrombin (2 U/mL) and ROS production was measured by ﬂow cytometry. Data are mean7SEM (n¼3), ***Pr0.001.
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ROS response with the same concentrations (150–250 mM) that
were required for optimum platelet aggregation (Fig. 1C). Ad-
ditionally, at optimal concentrations, thrombin elicited a much
higher response in comparison to PAR1 activation alone (Fig. 1D),
suggesting a more predominant role for PAR4 or GPIbα in
thrombin-induced ROS production.
3.2. Thrombin-induced ROS production requires PAR4, but not PAR1
Although both PAR1 and PAR4 agonists could generate ROS, the
relative contribution of these receptors in thrombin-induced ROS
production remained unclear. Speciﬁc blockade of PAR1 by
SCH79797 (1 mM; Fig. 2A) did not inhibit ROS production induced
by 2 U/mL thrombin, but signiﬁcantly potentiated the level of ROS
detected. This was conﬁrmed with a second PAR1 antagonist,
BMS200261 (1 mM; Supplement Fig. 1). In contrast, pre-treatment
with the PAR4 antagonist, tcY-NH2 (400 mM), signiﬁcantly in-
hibited ROS production (Fig. 2A). These data suggest a novel role
for PAR4 in thrombin-induced ROS generation in platelets in-
dependent of PAR1. The speciﬁcity of these antagonists was con-
ﬁrmed by their effect on the response to the relevant PAR agonist
peptide (data not shown).
To conﬁrm the role of PAR4 in thrombin-induced ROS forma-
tion, ROS production was assessed in platelets isolated from wild-
type (WT) and PAR4-deﬁcient mice (PAR4 KO). While basal ROS
production in platelets was similar between the two mouse
strains, stimulation with 2 U/mL thrombin induced signiﬁcant ROS
generation in WT mouse platelets, ROS formation was at back-
ground levels in platelets from PAR4 KO mice (Fig. 2B). Platelets
derived from PAR4 KO mice readily generated ROS in response to
the GPVI-speciﬁc agonist, collagen-related peptide (CRP;
10 mg/mL) or the combination of the protein kinase C activator,
phorbol myristoyl acetate (PMA; 10 mM) and the calcium iono-
phore, A23187 (20 mM) (Supplement Fig. 2).
3.3. Thrombin-induced ROS production is GPIbα-dependent
In addition to PAR1 and PAR4, thrombin also binds GPIbα [9],
although a role for GPIbα in ROS production has not beenpreviously explored. To investigate the contribution of GPIbα in
thrombin-induced ROS generation, human platelets were treated
with Nk protease, that has been shown to speciﬁcally cleave GPIbα
between amino acid residues Tyr276-Asp277, thus removing the
GPIbα thrombin binding site [28]. Nk protease treatment
(10 mg/mL for 30 min) consistently removed 499% of intact GPIbα
(Supplement Fig. 3). Nk protease-treated platelets failed to pro-
duce ROS in response to thrombin (Fig. 3A) but generated ROS
normally when treated with CRP (Fig. 3B). This suggests that
GPIbα is required, along with PAR4 for thrombin-induced ROS
production in human platelets. When stimulated with PAR4-AP,
platelets showed signiﬁcantly less ROS generation in the absence
of the GPIbα N-terminal region (Fig. 3C), however the response to
PAR1 agonist remained normal (Fig. 3D). Consistently, aggregation
was ablated in Nk-treated platelets when stimulated with PAR4-AP
(Fig. 3E), implying a functional association between GPIbα and
PAR4.
A potential synergy between PAR4 and GPIbα in thrombin-in-
duced ROS generation was conﬁrmed using mouse platelets,
which express PAR3 and PAR4 but not PAR1. When murine pla-
telets were treated with Nk protease to prevent engagement of
GPIbα by thrombin, ROS generation was signiﬁcantly inhibited
(Fig. 3F), indicating that GPIbα may act as an accessory receptor
and aid the engagement of PAR4 by thrombin both in murine and
human platelets.
3.4. ROS formation occurs through ligation and activation of GPIbα
To further understand the role of GPIbα in ROS formation, we
used COS-7 cells stably transfected for cell surface expression of a
recombinant von Willebrand Factor (VWF)-A1 domain containing
a R543W gain-of-function point mutation as a GPIbα speciﬁc
agonist (R543W cells). The A1 domain of VWF on R543W cells is in
a constitutively open and active conformation on the cell mem-
brane as a GPI-linked construct [32]. Surface expression was
conﬁrmed using the VWF-speciﬁc antibody, 5D2, with no binding
to non-transfected (WT) cells (Supplement Fig. 4). R543W cells,
but not WT cells, induced ROS in human platelets (Fig. 4A), which
was inhibited by 5D2 (10 mg/mL), which blocks the GPIb binding
Fig. 3. GPIbα is required for thrombin-induced ROS generation. Human platelets þ/ Nk protease treatment, and labelled with 10 mM H2DCFDA,were stimulated with
(A) 2 U/mL thrombin (B) 10 mg/mL CRP, (C) 250 mM PAR4-AP or (D) 50 mM PAR1-AP, and ROS production was measured by ﬂow cytometry. Data are mean7SEM (n¼4).
(E) Washed human platelets þ/ Nk protease treatment were stimulated with 250 mM PAR4-AP for 3 min and monitored for platelet aggregation by light transmission
aggregometry using a PAP4 platelet aggregometer. Data are mean7SEM (n¼4). (F) H2DCFDA labelled mouse platelets þ/ Nk protease treatment were stimulated with
thrombin (2 U/mL) and monitored for ROS production by ﬂow cytometry. Data are mean7SEM (n¼3). *Pr0.05, **Pr0.01, ***Pr0.001. ns¼statistical nonsigniﬁcance.
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which blocks the VWF binding site on GPIb (Fig. 4B). These data
demonstrate that engagement through GPIbα alone is sufﬁcient to
initiate platelet ROS formation.
3.5. NOX1 is the main source of ROS downstream of GPIbα and PAR
activation
We have previously shown NOX1 is the main NADPH oxidaseisoform involved in CRP-dependent ROS generation through the
platelet collagen receptor, GPVI [7]. Here, we explored the role of
NOX1 in ROS formation induced by thrombin using the NOX1 in-
hibitor, ML171 (5 mM). ML171 signiﬁcantly inhibited ROS genera-
tion when platelets were activated with thrombin, R543W cells or
PAR4-AP (Fig. 5A). These results suggest that platelet-derived ROS
generation is mainly NOX1-dependent regardless of the agonist
employed.
Fig. 4. ROS formation occurs through ligation and activation of GPIbα. (A) H2DCFDA labelled human platelets were stimulated with WT or R543W COS-7 cells (1:50; cell:
platelet ratio) and monitored for ROS production by ﬂow cytometry. Data are mean7SEM (n¼3). (B) H2DCFDA labelled human platelets pre-treated with either the GPIbα-
function blocking antibody, AK2 (20 mg/mL) or the VWF-function blocking antibody 5D2 (10 mg/mL) were stimulated with R543W cells (1:50; cell:platelet ratio) and
monitored for ROS production. Data are mean7SEM (n¼3). *Pr0.05, **Pr0.01, ***Pr0.001.
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generation
We recently demonstrated that FAK is important for down-
stream signalling leading to ROS formation when platelets are
stimulated with CRP [30]. The FAK inhibitor, PF-228 (1 mM), also
inhibited ROS formation when platelets were stimulated with
thrombin, R543W cells or PAR4-AP (Fig. 5B), suggesting that FAK
also plays a functional role downstream of both GPIbα and PAR4
following thrombin-induced ROS production.4. Discussion
Human PAR4 is a low afﬁnity thrombin receptor initiating
downstream signalling events following primary activation of
platelets through PAR1 [34]. In this study, we identiﬁed a novel
role for PAR4 in mediating thrombin-induced ROS production that
was not shared by PAR1. Additionally, the potential for involve-
ment of GPIbα in platelet-derived ROS generation was conﬁrmed
with a GPIbα-speciﬁc agonist. The combined data suggest GPIbα is
required to facilitate the interaction of thrombin with PAR4 on the
platelet membrane and implies a functional association between
these two receptors in human and mouse platelets.Fig. 5. ROS generation via GPIbα and PAR activation is mediated through FAK and NOX1
5 mMML171, or (B) FAK inhibitor, 1 mM PF-228, for 10 min, then stimulated with thrombin
monitored for ROS production by ﬂow cytometry. Data are mean7SEM (n¼3–6). *PrHigh concentrations of thrombin are typically required for
PAR4 activation. In this study thrombin concentrations of 1 U/mL
or greater, stimulated ROS formation consistent with an important
role for PAR4. In line with previous studies [3], higher concentra-
tions of PAR1-AP were required to induce ROS formation than
were required to induce maximal platelet aggregation. In com-
parison, PAR4-AP concentrations required for maximum aggrega-
tion response induced signiﬁcant ROS generation. While, a recent
study associated platelet activation via PAR4 with the redox sig-
nalling molecule 12-LOX [35], to the best of our knowledge the
present results are the ﬁrst report of a role for PAR4 in platelet-
derived ROS generation. Pharmacological antagonists acting at
PAR1 (SCH79797) or PAR4 (tcY-NH2) conﬁrmed a novel role for
PAR4, but not PAR1, in thrombin-mediated ROS generation. Inter-
estingly, SCH79797 actually potentiated thrombin-induced ROS
generation. This suggests that in the absence of functional PAR1,
ROS generation may be increased due to more thrombin being
available to bind PAR4, and is consistent with PAR1 not being in-
volved in thrombin-induced ROS generation.
Previous studies have shown a physical association of the GPIb-
IX-V complex with other important signalling surface receptor on
platelets, GPVI and FcγRIIa [32,36–38]. While GPVI- and FcγRIIa-
dependent signalling results in ROS formation [33,39], the role of
GPIbα itself in platelet ROS generation is not clear. In this study,. H2DCFDA labelled human platelets were pre-treated with the (A) NOX1 inhibitor,
(1 U/mL), R543W cells (1:50; cell:platelet ratio) or PAR4-AP (250 mM) for 2 min and
0.05, **Pr0.01, ***Pr0.001.
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tease, the thrombin-induced ROS response was completely abol-
ished and the platelets also responded poorly to PAR4-AP. These
results suggest a possible functional relationship between GPIbα
and PAR4 on the platelet surface. PAR4-AP-induced platelet ag-
gregation was also reduced following removal of the GPIbα
thrombin-binding domain, but not abolished, suggesting GPIbα is
required for optimal PAR4 activation, further supporting a poten-
tial link between these two receptors. Thrombin-induced ROS
generation in WT mouse platelets was also decreased by Nk pro-
tease treatment, supporting a functional cooperation between
GPIbα and PAR4 in mouse platelets. In contrast to human platelets,
PAR3 is also known to enhance PAR4 activation [40]. To date, there
is no reported connection between PAR4 and GPIbα. There is
evidence that GPIbα acts as a co-factor for PAR1 but not PAR4
activation [41], and can amplify PAR1 responses [42]. A possible
explanation for this discrepancy is that the GPIbα association with
PAR4 is masked by that with PAR1 with respect to platelet ag-
gregation but evident with ROS generation at higher thrombin
concentrations, which do not involve PAR1. The capacity of GPIbα
to generate ROS was conﬁrmed using the GPIbα speciﬁc agonist,
R543W cells.
Downstream of thrombin binding and GPIbα/PAR4 activation,
ROS generation was found to require both FAK and NOX1. These
data suggest that agonist-dependent ROS production in platelets is
mainly derived through NOX1 activation, consistent with our
previous report for GPVI-dependent ROS formation [7]. In addi-
tion, these data also conﬁrm that common signalling proteins such
as FAK are involved in both GPIbα- and PAR4-dependent ROS
production. Whether or not PAR4 directly activates NOX1 and/or
like GPIb-IX and GPVI directly interacts with TRAF4 [25], was not
determined in this study. PAR4 could also potentially utilise GPIb-
associated NOX. The detailed mechanisms for PAR4-dependent
activation of downstream NOX1 and FAK remain to be elucidated.
It is clear from this study that both GPIbα and PAR4 play a
prominent role in thrombin-induced platelet ROS generation. In
the functional absence of either receptor on human platelets,
thrombin cannot elicit ROS production, implying a mechanism
that involves both receptors. Anti-PAR1 drugs, such as Vorapaxar,
are associated with severe bleeding risks [43,44]. Shifting focus to
the GPIbα-PAR4 axis could provide an alternate anti-platelet
therapeutic strategy [45].Contribution of authors
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